Dendreon upbeat on ability to make Provenge next year

Dendreon expects to reach full manufacturing capacity for experimental prostate cancer drug Provenge by mid-2011, and will immediately launch sales of the drug when it is approved by U.S. regulators, the company's CEO said at the J.P. Morgan conference. Story